TABLE 3

Maximum Number of Palivizumab Doses for RSV Prophylaxis of Preterm Infants Without CLD, Based on Birth Date, Gestational Age, and Presence of Risk Factors (Shown for Areas Beginning Prophylaxis on November 1st)

Month of BirthMaximum No. of Doses for Season Beginning Nov 1
≤28 wk 6 d Gestation and <12 mo of Age at Start of Season29 wk 0 d Through 31 wk 6 d Gestation and <6 mo of Age at Start of Season32 wk 0 d Through 34 wk 6 d and With Risk Factora
Nov 1–Mar 31 of previous RSV season5b0c0d
Apr50c0d
May550d
Jun550d
Jul550d
Aug551e
Sep552e
Oct553e
Nov553e
Dec443e
Jan333e
Feb222e
Mar111e
  • If the infant is discharged from the hospital during RSV season, fewer doses may be required.

  • a Risk factors: infant attends child care or has sibling younger than 5 years.

  • b Some of these infants may have received 1 or more doses of palivizumab in the previous RSV season if discharged from the hospital during that season; if so, they still qualify for up to 5 doses during their second RSV season.

  • c Zero doses because infant will be older than 6 months at the start of RSV season.

  • d Zero doses because infant will be older than 90 days of age at start of RSV season.

  • e On the basis of the age of patients at the time of discharge from the hospital, fewer doses may be required, because these infants will receive 1 dose every 30 days until the infant is 90 days of age.